Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark
Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Meth...
Gespeichert in:
| Veröffentlicht in: | International journal of technology assessment in health care 2010-04, Vol.26 (2), p.183-191 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 191 |
|---|---|
| container_issue | 2 |
| container_start_page | 183 |
| container_title | International journal of technology assessment in health care |
| container_volume | 26 |
| creator | Olsen, Jens Jepsen, Martin Rudbeck |
| description | Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1–3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted. Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon. Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival. |
| doi_str_mv | 10.1017/S0266462310000085 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_743679913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0266462310000085</cupid><sourcerecordid>743679913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-ce237f37c56b98fafbf0131e1c39efc771da8f87fd8b95d9ec8cc9e1c41d70013</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS1ERbeFH8AFWVw4hdpxNnaOqKW7oEotKqDeLMceVy6JvbWdFfz7OtqlSKAKX3x43zy9N4PQa0reU0L5yTWp27Zpa0bJ_MTyGVrQhtOqZY14jhazXM36ITpK6Y4QykhHXqDDmrCuZnW9QGE9jcrjjdq4YQij2ro4JZyj8ml0KbngsfIG65ByBdaCzm4LHlLCwWLncwxm0s7f4vtJmei2agCf8frqO94qXQSVZwvn8Rn4UcUfL9GBVUOCV_v_GH07__j1dF1dXK4-nX64qHTT0FxpqBm3jOtl23fCKtvbEp4C1awDqzmnRgkruDWi75amAy207orcUMPnnsfo3c53E8P9BCnLUkfDMCgPYUqSN6zlXUfZ_0nGhBCUi0K-_Yu8C1P0pYasKWHFjs92dAfpGFKKYOUmutL8l6REzleT_1ytzLzZG0_9COZx4veZClDtAJcy_HzUyz5lyxlfynb1RZ7f3Fx_Xq-YvCo824dQYx-duYU_UZ-O8QApwLJm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210379973</pqid></control><display><type>article</type><title>Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark</title><source>MEDLINE</source><source>Cambridge University Press Journals Complete</source><creator>Olsen, Jens ; Jepsen, Martin Rudbeck</creator><creatorcontrib>Olsen, Jens ; Jepsen, Martin Rudbeck</creatorcontrib><description>Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1–3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted. Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon. Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival.</description><identifier>ISSN: 0266-4623</identifier><identifier>EISSN: 1471-6348</identifier><identifier>DOI: 10.1017/S0266462310000085</identifier><identifier>PMID: 20392322</identifier><language>eng</language><publisher>New York, USA: Cambridge University Press</publisher><subject>Adult ; Age ; Aged ; Aged, 80 and over ; Alphapapillomavirus - immunology ; Cervical cancer ; Cost analysis ; Cost control ; Cost estimates ; Cost-effectiveness ; Denmark ; Female ; Genital warts ; Herd immunity ; Heterosexuality ; HPV transmission ; HPV vaccination ; Human papillomavirus ; Humans ; Immunity (Disease) ; Immunization Programs - economics ; Infections ; Medical screening ; Middle Aged ; Papillomavirus Infections - prevention & control ; Papillomavirus Infections - transmission ; Papillomavirus Vaccines - economics ; Papillomavirus Vaccines - therapeutic use ; Population ; Quality of life ; Sexual behavior ; Vaccines ; Womens health ; Young Adult</subject><ispartof>International journal of technology assessment in health care, 2010-04, Vol.26 (2), p.183-191</ispartof><rights>Copyright © Cambridge University Press 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-ce237f37c56b98fafbf0131e1c39efc771da8f87fd8b95d9ec8cc9e1c41d70013</citedby><cites>FETCH-LOGICAL-c441t-ce237f37c56b98fafbf0131e1c39efc771da8f87fd8b95d9ec8cc9e1c41d70013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0266462310000085/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,776,780,27901,27902,55603</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20392322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olsen, Jens</creatorcontrib><creatorcontrib>Jepsen, Martin Rudbeck</creatorcontrib><title>Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark</title><title>International journal of technology assessment in health care</title><addtitle>Int J Technol Assess Health Care</addtitle><description>Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1–3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted. Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon. Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alphapapillomavirus - immunology</subject><subject>Cervical cancer</subject><subject>Cost analysis</subject><subject>Cost control</subject><subject>Cost estimates</subject><subject>Cost-effectiveness</subject><subject>Denmark</subject><subject>Female</subject><subject>Genital warts</subject><subject>Herd immunity</subject><subject>Heterosexuality</subject><subject>HPV transmission</subject><subject>HPV vaccination</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immunity (Disease)</subject><subject>Immunization Programs - economics</subject><subject>Infections</subject><subject>Medical screening</subject><subject>Middle Aged</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Infections - transmission</subject><subject>Papillomavirus Vaccines - economics</subject><subject>Papillomavirus Vaccines - therapeutic use</subject><subject>Population</subject><subject>Quality of life</subject><subject>Sexual behavior</subject><subject>Vaccines</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>0266-4623</issn><issn>1471-6348</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkUFv1DAQhS1ERbeFH8AFWVw4hdpxNnaOqKW7oEotKqDeLMceVy6JvbWdFfz7OtqlSKAKX3x43zy9N4PQa0reU0L5yTWp27Zpa0bJ_MTyGVrQhtOqZY14jhazXM36ITpK6Y4QykhHXqDDmrCuZnW9QGE9jcrjjdq4YQij2ro4JZyj8ml0KbngsfIG65ByBdaCzm4LHlLCwWLncwxm0s7f4vtJmei2agCf8frqO94qXQSVZwvn8Rn4UcUfL9GBVUOCV_v_GH07__j1dF1dXK4-nX64qHTT0FxpqBm3jOtl23fCKtvbEp4C1awDqzmnRgkruDWi75amAy207orcUMPnnsfo3c53E8P9BCnLUkfDMCgPYUqSN6zlXUfZ_0nGhBCUi0K-_Yu8C1P0pYasKWHFjs92dAfpGFKKYOUmutL8l6REzleT_1ytzLzZG0_9COZx4veZClDtAJcy_HzUyz5lyxlfynb1RZ7f3Fx_Xq-YvCo824dQYx-duYU_UZ-O8QApwLJm</recordid><startdate>201004</startdate><enddate>201004</enddate><creator>Olsen, Jens</creator><creator>Jepsen, Martin Rudbeck</creator><general>Cambridge University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7U5</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>H94</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>L7M</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201004</creationdate><title>Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark</title><author>Olsen, Jens ; Jepsen, Martin Rudbeck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-ce237f37c56b98fafbf0131e1c39efc771da8f87fd8b95d9ec8cc9e1c41d70013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alphapapillomavirus - immunology</topic><topic>Cervical cancer</topic><topic>Cost analysis</topic><topic>Cost control</topic><topic>Cost estimates</topic><topic>Cost-effectiveness</topic><topic>Denmark</topic><topic>Female</topic><topic>Genital warts</topic><topic>Herd immunity</topic><topic>Heterosexuality</topic><topic>HPV transmission</topic><topic>HPV vaccination</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immunity (Disease)</topic><topic>Immunization Programs - economics</topic><topic>Infections</topic><topic>Medical screening</topic><topic>Middle Aged</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Infections - transmission</topic><topic>Papillomavirus Vaccines - economics</topic><topic>Papillomavirus Vaccines - therapeutic use</topic><topic>Population</topic><topic>Quality of life</topic><topic>Sexual behavior</topic><topic>Vaccines</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olsen, Jens</creatorcontrib><creatorcontrib>Jepsen, Martin Rudbeck</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of technology assessment in health care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olsen, Jens</au><au>Jepsen, Martin Rudbeck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark</atitle><jtitle>International journal of technology assessment in health care</jtitle><addtitle>Int J Technol Assess Health Care</addtitle><date>2010-04</date><risdate>2010</risdate><volume>26</volume><issue>2</issue><spage>183</spage><epage>191</epage><pages>183-191</pages><issn>0266-4623</issn><eissn>1471-6348</eissn><abstract>Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1–3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted. Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon. Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival.</abstract><cop>New York, USA</cop><pub>Cambridge University Press</pub><pmid>20392322</pmid><doi>10.1017/S0266462310000085</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0266-4623 |
| ispartof | International journal of technology assessment in health care, 2010-04, Vol.26 (2), p.183-191 |
| issn | 0266-4623 1471-6348 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_743679913 |
| source | MEDLINE; Cambridge University Press Journals Complete |
| subjects | Adult Age Aged Aged, 80 and over Alphapapillomavirus - immunology Cervical cancer Cost analysis Cost control Cost estimates Cost-effectiveness Denmark Female Genital warts Herd immunity Heterosexuality HPV transmission HPV vaccination Human papillomavirus Humans Immunity (Disease) Immunization Programs - economics Infections Medical screening Middle Aged Papillomavirus Infections - prevention & control Papillomavirus Infections - transmission Papillomavirus Vaccines - economics Papillomavirus Vaccines - therapeutic use Population Quality of life Sexual behavior Vaccines Womens health Young Adult |
| title | Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A51%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20papillomavirus%20transmission%20and%20cost-effectiveness%20of%20introducing%20quadrivalent%20HPV%20vaccination%20in%20Denmark&rft.jtitle=International%20journal%20of%20technology%20assessment%20in%20health%20care&rft.au=Olsen,%20Jens&rft.date=2010-04&rft.volume=26&rft.issue=2&rft.spage=183&rft.epage=191&rft.pages=183-191&rft.issn=0266-4623&rft.eissn=1471-6348&rft_id=info:doi/10.1017/S0266462310000085&rft_dat=%3Cproquest_cross%3E743679913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210379973&rft_id=info:pmid/20392322&rft_cupid=10_1017_S0266462310000085&rfr_iscdi=true |